AGM
CRDF icon

Alpine Global Management’s Cardiff Oncology CRDF Stock Holding History

Alpine Global Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,924
Closed -$84.2K – 221
2024
Q2 		$84.2K Buy
+37,924
New +$143K 0.01% 430
2014
Q2 		– Sell
-347
Closed -$143K – 187
2014
Q1 		$143K Sell
347
-243
-41% -$105K 0.12% 127
2013
Q4 		$244K Buy
+590
New +$263K 0.39% 53

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alpine Global Management's CRDF Position: Q3 2024 in Review

Alpine Global Management sold out of Cardiff Oncology (CRDF) in Q3 2024, closing a stake of 37,924 shares — an estimated $84.2K sold.

Alpine Global Management first reported a position in CRDF in Q4 2013 and held it in 3 quarters. The position peaked at $244K in Q4 2013. 83 funds tracked by Wall St. Rank hold CRDF as of Q3 2024.

  • Alpine Global Management reported no remaining Cardiff Oncology position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 37,924 Cardiff Oncology shares in Q3 2024, an estimated $84.2K.
  • Alpine Global Management first reported a position in Cardiff Oncology in Q4 2013 and held it in 3 quarters.
  • Alpine Global Management's Cardiff Oncology position peaked at $244K in Q4 2013.
  • 83 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.